C.R.S. § 25.5-5-422

(1) As used in this section, “FDA” means the food and drug administration in the United States department of health and human services. (2) Notwithstanding any provision of law to the contrary, beginning January 1, 2020, each MCE that provides prescription drug benefits for the treatment of substance use disorders shall: (a) Not impose any prior authorization requirements on any prescription medication approved by the FDA for the treatment of substance use disorders; (b) Not impose any step therapy requirements as a prerequisite to authorizing coverage for a prescription medication approved by the FDA for the treatment of substance use disorders; and (c) Not exclude coverage for any prescription medication approved by the FDA for the treatment of substance use disorders and any associated counseling or wraparound services solely on the grounds that the medications and services were court ordered.